Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on March 19
Presentation to be Webcast Live at 3:30 p.m. ET / 2:30 p.m. CT
BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NAS: ANIK) a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, today announced that Chief Executive Officer Dr. Charles Sherwood will be presenting at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19, 2013 at 3:30 p.m. ET / 2:30 p.m. CT. The conference is being held at the Westin Michigan Avenue in Chicago.
An audio webcast of the presentation will be available live and may be accessed via the "Investor Relations" section of Anika's website at www.anikatherapeutics.com. An archive of the presentation also will be available on the website.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by Orthovisc®, a treatment for osteoarthritis of the knee; to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika's Italian subsidiary, Anika Therapeutics S.r.l, provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in areas such as advanced wound treatment and ear, nose and throat care. Its regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
President and CEO
KEYWORDS: United States North America Illinois Massachusetts
The article Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on March 19 originally appeared on Fool.com.